Yellow Fever

Yellov fever is the only disease where vaccination is required before entering several countries in Africa and South America. Yellow fever vaccination is recommended before entering several countries please refer to list of countries.

Vaccination: Yellow fever vaccine is a live virus vaccine, which has been used for several decades and is effective in protecting.

Protection: A single dose confers immunity lasting 10 years or more. Adults and children over 9 months can take this vaccine. A booster dose is needed every 10 years.

Side effects: Yellow fever vaccine generally has few side effects; fewer than 5% of vaccines develop mild headache, muscle pain, or other minor symptoms 5 to 10 days after vaccination.

Yellow fever Vaccination Resource:

The Safety of Yellow Fever Vaccine 17D or 17DD in Children, Pregnant Women, HIV+ Individuals, and Older Persons: Systematic Review.
Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T.
Am J Trop Med Hyg. 2012 Feb;86(2):359-72
Vaccination against infection in patients with multiple sclerosis.
Loebermann M, Winkelmann A, Hartung HP, Hengel H, Reisinger EC, Zettl UK.
Nat Rev Neurol. 2012 Jan 24. doi: 10.1038/nrneurol.2012.8. [Epub ahead of print
Plasma HIV-RNA is the key determinant of long-term antibody persistence following Yellow fever immunization in a cohort of 364 HIV-infected patients.
Pacanowski J, Lacombe K, Campa P, Dabrowska M, Poveda JD, Meynard JL, Poirot JL, Fonquernie L, Girard PM.
J Acquir Immune Defic Syndr. 2012 Jan 19. [Epub ahead of print
Methodological issues with the risk of relapse study in patients with multiple sclerosis after yellow Fever vaccination.
Pool V, Gordon DM, Decker M.
Arch Neurol. 2012 Jan;69(1):144. No abstract available.
Municipalities of higher vulnerability to Sylvatic Yellow Fever occurrence in the São Paulo State, Brazil.
Moreno ES, Barata Rde C.
Rev Inst Med Trop Sao Paulo. 2011 Dec;53(6):335-9
Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study.
Roukens AH, Soonawala D, Joosten SA, de Visser AW, Jiang X, Dirksen K, de Gruijter M, van Dissel JT, Bredenbeek PJ, Visser LG.
PLoS One. 2011;6(12):e27753. Epub 2011 Dec 7
Risks to Young Volunteers in International Social Projects.
Martin J, Rieke B, Neppach K, Hillebrandt D, Küpper T.
Ann Occup Hyg. 2011 Dec 8. [Epub ahead of print
Global TravEpiNet: A National Consortium of Clinics Providing Care to International Travelers--Analysis of Demographic Characteristics, Travel Destinations, and Pretravel Healthcare of High-Risk US International Travelers, 2009-2011.
Larocque RC, Rao SR, Lee J, Ansdell V, Yates JA, Schwartz BS, Knouse M, Cahill J, Hagmann S, Vinetz J, Connor BA, Goad JA, Oladele A, Alvarez S, Stauffer W, Walker P, Kozarsky P, Franco-Paredes C, Dismukes R, Rosen J, Hynes NA, Jacquerioz F, McLellan S, Hale D, Sofarelli T, Schoenfeld D, Marano N, Brunette G, Jentes ES, Yanni E, Sotir MJ, Ryan ET; the Global TravEpiNet Consortium.
Clin Infect Dis. 2012 Feb;54(4):455-462. Epub 2011 Dec 5
Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review.
Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T.
Curr Drug Saf. 2011 Jul;6(3):145-54
Yellow fever vaccination in organ transplanted patients: is it safe? A multicenter study.
Azevedo LS, Lasmar EP, Contieri FL, Boin I, Percegona L, Saber LT, Selistre LS, Netto MV, Moreira MC, Carvalho RM, Bruno RM, Ferreira TC, David-Neto E.
Transpl Infect Dis. 2011 Oct 9. doi: 10.1111/j.1399-3062.2011.00686.x. [Epub ahead of print
Vaccination and risk of type 1 diabetes mellitus in active component U.S. Military, 2002-2008.
Duderstadt SK, Rose CE Jr, Real TM, Sabatier JF, Stewart B, Ma G, Yerubandi UD, Eick AA, Tokars JI, McNeil MM.
Vaccine. 2012 Jan 17;30(4):813-9. Epub 2011 Nov 8
Vaccination of travelers: how far have we come and where are we going?
Chen LH, Hill DR, Wilder-Smith A.
Expert Rev Vaccines. 2011 Nov;10(11):1609-20
Measles in a tertiary institution in bida, niger state, Nigeria: prevalence, immunization status and mortality pattern.
Adeboye M, Adesiyun O, Adegboye A, Eze E, Abubakar U, Ahmed G, Usman A, Amos S, Rotimi B.
Oman Med J. 2011 Mar;26(2):114-7
Intrathecal antibody production in two cases of yellow fever vaccine associated neurotropic disease in Argentina.
Pires-Marczeski FC, Martinez VP, Nemirovsky C, Padula PJ.
J Med Virol. 2011 Dec;83(12):2208-12. doi: 10.1002/jmv.22236
Yellow fever vaccine seroconversion in travelers.
Kay A, Chen LH, Sisti M, Monath TP.
Am J Trop Med Hyg. 2011 Oct;85(4):748-9
Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil.
de Melo AB, da Silva Mda P, Magalhães MC, Gonzales Gil LH, Freese de Carvalho EM, Braga-Neto UM, Bertani GR, Marques ET Jr, Cordeiro MT.
Am J Trop Med Hyg. 2011 Oct;85(4):739-47
Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans.
Qiao M, Shaw D, Forrat R, Wartel-Tram A, Lang J.
Am J Trop Med Hyg. 2011 Oct;85(4):724-31
Health conditions for travellers to Saudi Arabia for the pilgrimage to Mecca (Hajj).
[No authors listed]
Wkly Epidemiol Rec. 2011 Sep 23;86(39):425-8. English, French. No abstract available.
Revised recommendations for yellow fever vaccination for international travellers, 2011.
[No authors listed]
Wkly Epidemiol Rec. 2011 Sep 9;86(37):401-11. English, French. No abstract available.
[West Nile virus expanding in Europe].
Reusken CB, van Maanen CK, Martina BE, Sonder GJ, van Gorp EC, Koopmans MP.
Ned Tijdschr Geneeskd. 2011;155(39):A3715. Review. Dutch.
First 1 2 3 4 5 6 7 8 9 Next Last 38/754 Jump: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38

To top Back to list of vaccination • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster